AMP Kinase Activation Mitigates Dopaminergic Dysfunction and Mitochondrial Abnormalities in Drosophila Models of Parkinson's Disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Mutations in parkin and LRRK2 together account for the majority of familial Parkinson's disease (PD) cases. Interestingly, recent evidence implicates the involvement of parkin and LRRK2 in mitochondrial homeostasis. Supporting this, we show here by means of the Drosophila model system that, like parkin, LRRK2 mutations induce mitochondrial pathology in flies when expressed in their flight muscles, the toxic effects of which can be rescued by parkin coexpression. When expressed specifically in fly dopaminergic neurons, mutant LRRK2 results in the appearance of significantly enlarged mitochondria, a phenotype that can also be rescued by parkin coexpression. Importantly, we also identified in this study that epigallocatechin gallate (EGCG), a green tea-derived catechin, acts as a potent suppressor of dopaminergic and mitochondrial dysfunction in both mutant LRRK2 and parkin-null flies. Notably, the protective effects of EGCG are abolished when AMP-activated protein kinase (AMPK) is genetically inactivated, suggesting that EGCG-mediated neuroprotection requires AMPK. Consistent with this, direct pharmacological or genetic activation of AMPK reproduces EGCG's protective effects. Conversely, loss of AMPK activity exacerbates neuronal loss and associated phenotypes in parkin and LRRK mutant flies. Together, our results suggest the relevance of mitochondrial-associated pathway in LRRK2 and parkin-related pathogenesis, and that AMPK activation may represent a potential therapeutic strategy for these familial forms of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 1×
“Another attractive explanation regarding AMPKmediated neuroprotection came from recent studies demonstrating that AMPK, like parkin, can regulate mitophagy (Egan et al., 2011; Kim et al., 2011).”
BackgroundDauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Parkin is recruited selectively to impaired mitochondria and promotes their autophagy
Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200809125 · Cited by 4,026 · cited 1×
“In particular, a recent landmark paper identified parkin as a key mediator of mitochondrial quality control (Narendra et al., 2008).”
BackgroundPhosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 1×
“Further, Drosophila parkin mutants exhibit pronounced mitochondrial abnormalities in their flight musculature, a phenotype that can be rescued by overexpression of wild-type human parkin (Greene et al., 2003; Park et al., 2006; Wang et al., 2007).”
BackgroundSelf-citationAMP-activated protein kinase: an energy sensor that regulates all aspects of cell function
Hardie, D. G. (2011) · Genes & Development · doi:10.1101/gad.17420111 · Cited by 1,638 · cited 3×
“or genetic activation of AMP-kinase (AMPK), a key cellular regulator of energy metabolism (Hardie, 2011), offers significant protection against DA and mitochondrial dysfunction in both LRRK2 and parkin mutant flies.”
BackgroundInfluentialMitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., & Pallanck, L. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737556100 · Cited by 1,203 · cited 4×
“Given that LRRK2 G2019S-expressing flies seem to phenocopy the reported mitochondrial phenotype of parkin-null flies (Greene et al., 2003), and that parkin protects against LRRK2 G2019Sinduced neurotoxicity (Ng et al., 2009), we surmised that parkin overexpression may potentially rescue the…”
BackgroundInfluentialShults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326 · cited 1×
“Supporting this, several postmortem studies have demonstrated a significant reduction in the activity of mitochondrial complex I as well as ubiquinone (coenzyme Q10) in the substantia nigra of PD brains (Schapira et al., 1989; Shults et al., 1997).”
BackgroundSpasić, M. R., Callaerts, P., & Norga, K. K. (2009) · The Neuroscientist · doi:10.1177/1073858408327805 · Cited by 109 · cited 2×
“Besides possessing antioxidant properties, EGCG has been reported to activate AMPK, and emerging evidence suggests that AMPK activation may be neuroprotective (Hwang et al., 2009; Spasić et al., 2009).”
Background
Cited by
Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment
Golpich, M., Amini, E., Mohamed, Z., Azman Ali, R., Mohamed Ibrahim, N., & Ahmadiani, A. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12655 · Cited by 532
AMPK at the Nexus of Energetics and Aging
Burkewitz, K., Zhang, Y., & Mair, W. B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.002 · Cited by 483
“Genetic activation of AMPK also protects against neuronal loss in Parkinson’s disease models in Drosophila (Ng et al., 2012).”
BackgroundInsulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Kawabata, K., Mukai, R., & Ishisaka, A. (2015) · Food & Function · doi:10.1039/c4fo01178c · Cited by 326
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
Rational Design of Nanocarriers for Intracellular Protein Delivery
Qin, X., Yu, C., Wei, J., Li, L., Zhang, C., Wu, Q., Liu, J., Yao, S. Q., & Huang, W. (2019) · Advanced Materials · doi:10.1002/adma.201902791 · Cited by 280
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Moors, T. E., Hoozemans, J. J. M., Ingrassia, A., Beccari, T., Parnetti, L., Chartier-Harlin, M.-C., & van de Berg, W. D. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0154-3 · Cited by 278
Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice
Patil, S. P., Jain, P. D., Ghumatkar, P. J., Tambe, R., & Sathaye, S. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.07.046 · Cited by 273
Towards applications of bioentities@MOFs in biomedicine
Velásquez-Hernández, M. D. J., Linares-Moreau, M., Astria, E., Carraro, F., Alyami, M. Z., Khashab, N. M., Sumby, C. J., Doonan, C. J., & Falcaro, P. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213651 · Cited by 233
Katila, N., Bhurtel, S., Shadfar, S., Srivastav, S., Neupane, S., Ojha, U., Jeong, G.-S., & Choi, D.-Y. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.015 · Cited by 169
Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162
Statins and the Brain: More than Lipid Lowering Agents?
Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170703101816 · Cited by 116
Hou, Y.-S., Guan, J.-J., Xu, H.-D., Wu, F., Sheng, R., & Qin, Z.-H. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00285-15 · Cited by 87
Shah, S. Z. A., Zhao, D., Hussain, T., & Yang, L. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.09.004 · Cited by 55
“Ng and coworkers demonstrated that AMPK activation rescued dopaminergic neuron degeneration via modulation of mitochondrial dynamics in a Drosophila model of PD (Ng et al., 2012).”
Background
Metadata
- Authors
- Ng, C.-H., Guan, M. S. H., Koh, C., Ouyang, X., Yu, F., Tan, E.-K., O'Neill, S. P., Zhang, X., Chung, J., & Lim, K.-L.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2012-10-10
- Volume
- 32
- Issue
- 41
- Pages
- 14311-14317
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1999292282
- Cited by
- 176
- References
- 9
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.